Immuneering reports 40% ORR, 80% DCR from IMM-1-104 combo in pancreatic cancer

Immuneering Corp

First patient had complete response; second unconfirmed partial; third/fourth stable disease; fifth equivocal progressive disease.
80% disease control rate and 40% overall response rate (RECIST) in first five patients; all remain on treatment.
DSMB approved enrollment of additional patients at 320 mg QD; dosing has begun.
Initial data from another Phase 2a arm of IMM-1-104 and Phase 1 data for IMM-6-415 expected by year-end 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.